Idiopathic Interstitial Fibrosis

  • Samuel P. Hammar


Fibrosis is a nonspecific reaction to injury typically occurring in association with or after a significant inflammatory process. In the case of a myocardial infarct, for example, the region of ischemic necrosis is eventually replaced by a dense fibrous scar. In skin, regions of surgical incision or traumatic laceration undergo fibrosis as part of the normal healing process. Similarly, the lung is an organ in which fibrotic reactions occur. In some instances, such as pulmonary infarcts, fibrosis may be part of a normal healing process, and the mechanism of fibrosis is relatively well understood. In other conditions, such as asbestosis, the etiology is apparent but the mechanism of fibrosis is poorly understood. In myocardial infarcts and wound healing, fibrosis serves a useful purpose. When it occurs in the interstitium of peripheral lung tissue, it has a deleterious effect, interfering with normal physiologic functions such as blood flow and gas diffusion.


Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Interstitial Lung Disease Interstitial Fibrosis Interstitial Pneumonitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Fulmer JD, Crystal RG. Interstitial lung disease. Curr Pulmonol 1797; 1: 1–65.Google Scholar
  2. 2.
    Keogh BA, Crystal RG. Chronic interstitial lung disease. Curr Pulmonol 1981; 3: 237–340.Google Scholar
  3. 3.
    Crystal RG, Gadek JE, Ferrans VJ, Fulmer JD, Line BR, Hunninghake GW. Interstitial lung disease: Current concepts of pathogenesis, staging and therapy. Am J Med 1981; 70: 542–568.PubMedGoogle Scholar
  4. 4.
    Crystal RG, Bitterman PB, Rennard SI, Hance AJ, Keogh BA. Interstitial lung diseases of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract. N Engl J Med 1984; 310: 154166, 235–244.PubMedGoogle Scholar
  5. 5.
    Katzenstein AA. Pathogenesis of “fibrosis” in interstitial pneumonia. An electron microscopic study. Hum Pathol 1985; 16: 1015–1024.PubMedGoogle Scholar
  6. 6.
    Katzenstein AA, Myers JL, Mazur MT. Acute interstitial pneumonia. A clinicopathologic, ultrastructural and cell kinetic study. Am J Surg Pathol 1986; 10: 256–267.PubMedGoogle Scholar
  7. 7.
    Pratt DS, Schwarz MI, May JJ, Dreisin RB. Rapidly fatal pulmonary fibrosis: The accelerated variant of interstitial pneumonitis. Thorax 1979; 34: 587–593.PubMedGoogle Scholar
  8. 8.
    Spencer H. Pneumonias due to rickettsiae, chlamydia, viruses and mycoplasma. In: Pathology of the lung. 4th Ed. Oxford: Pergamon, 1985: 222–259.Google Scholar
  9. 9.
    Hamman L, Rich AR. Fulminating diffuse interstitial fibrosis of the lungs. Trans Am Clin Climatol Assoc 1935; 51: 154–163.PubMedGoogle Scholar
  10. 10.
    Hamman L, Rich AR. Acute diffuse interstitial fibrosis of the lungs. Bull Johns Hopkins Hosp 1944; 74: 177–212.Google Scholar
  11. 11.
    Hasleton PS. Adult respiratory distress syndrome-a review. Histopathology 1983; 7: 307–332.PubMedGoogle Scholar
  12. 12.
    Olson J, Colby TV, Elliot CG. Hamman-Rich syndrome revisited. Mayo Clin Proc 1990; 65: 1538–1548.PubMedGoogle Scholar
  13. 13.
    Liebow AA, Carrington CB. The interstitial pneumonias. In: Simon M, Potchen EJ, Lemay M, eds. Frontiers of pulmonary radiology. New York: Grune & Stratton, 1969: 102–141.Google Scholar
  14. 14.
    Liebow AA, Steer A, Billingsley JG. Desquamative interstitial pneumonia. Am J Med 1965; 39: 369–404.PubMedGoogle Scholar
  15. 15.
    Carrington CB, Liebow AA. Lymphocytic interstitial pneumonia. Am J Pathol 1966; 48: 36a.Google Scholar
  16. 16.
    Scadding JG. Fibrosing alveolitis. Br Med J 1964; 2: 686.PubMedGoogle Scholar
  17. 17.
    Fishman AP. UIP, DIP and all that. N Engl J Med 1978; 298: 843–845.PubMedGoogle Scholar
  18. 18.
    Gough J. Fibrosing alveolitis. Br Med J 1964; 2: 818.Google Scholar
  19. 19.
    Scadding JG, Hinson KFW. Diffuse fibrosing alveolitis (diffuse interstitial fibrosis of the lungs). Correlation of histology at biopsy with prognosis. Thorax 1967; 22: 291–304.PubMedGoogle Scholar
  20. 20.
    Potter BP, Gerber IE. Acute diffuse interstitial fibrosis of the lungs: report of a Arch Intern Med 1948; 82: 113–124.Google Scholar
  21. 21.
    Stursa M. Interstitial pneumonia with chronic course. Cas Lek Ces 1949; 88: 464–466.Google Scholar
  22. 22.
    Beams AJ, Harmos O. Diffuse progressive interstitial fibrosis of lungs. Am J Med 1949; 7: 425–430.PubMedGoogle Scholar
  23. 23.
    Ferrari M, Cavbarrére NL, Botinelli MD, Mendilaharsu C, Giudice D. Neumofibrosis intersticial evolutiva: Una neuva entidad? Hoja Tisiol 1949; 9: 207–221.PubMedGoogle Scholar
  24. 24.
    Golden A, Tullis IF, Jr. Diffuse interstitial fibrosis of lungs. Mil Surg 1949;105:130–137.Google Scholar
  25. 25.
    Rubin EH, Lubliner R. The Hamman-Rich syndrome: review of the literature and analysis of 15 cases. Medicine (Baltimore) 1957; 36: 397–463.Google Scholar
  26. 26.
    Kourilsky R, Decroix G, Verley B, Voisin G, Matossy Y. Primary diffuse interstitial pulmonary fibrosis (Hamman-Rich syndrome). J Fr Med Chir Thorac 1959; 13: 637–674.PubMedGoogle Scholar
  27. 27.
    Livingstone JL, Lewis JG, Reid L, Jefferson KE. Diffuse interstitial pulmonary fibrosis: A clinical, radiological and pathological study based on 45 patients. Q J Med 1964; 33: 71–103.PubMedGoogle Scholar
  28. 28.
    Scadding JC. Diffuse pulmonary alveolar fibrosis. Thorax 1974; 29: 271–281.PubMedGoogle Scholar
  29. 29.
    Scadding JC. Chronic diffuse interstitial fibrosis of the lung. Br Med J 1960; 1: 443–448.PubMedGoogle Scholar
  30. 30.
    Hunninghake GW, Fauci AS. Pulmonary involvement in the collagen vascular diseases. Am Rev Respir Dis 1979; 119: 471–503.PubMedGoogle Scholar
  31. 31.
    Epler GR, Snider GL, Gaensler EA, Cathcart ES, Fitzgerald MX, Carrington CB. Bronchiolitis and bronchitis in connective tissue disease: A possible relationship to the use of penicillamine. JAMA 1979; 242: 528–532.PubMedGoogle Scholar
  32. 32.
    Cordier JF, Falconnet M, Moulin J, Brune J, Touraine R. Brochiolite severe et polyarthrite rheumatoide: Role tres probable de la d-penicillamine dans deux observations. Lyons Med 1980; 224: 113–114.Google Scholar
  33. 33.
    Athreya BH, Doughty RA, Bookspan M, Schumacher HR, Sewell EA, Chatten J. Pulmonary manifestations of juvenile rheumatoid arthritis. Clin Chest Med 1980; 1: 361–374.PubMedGoogle Scholar
  34. 34.
    Herzog CA, Miller RA, Hoidal JR. Bronchiolitis and rheumatoid arthritis. Am Rev Respir Dis 1981; 124: 636–639.PubMedGoogle Scholar
  35. 35.
    Salmeron G, Greenberg SD, Lidsky MD. Polymyositis and diffuse interstitial lung disease: A review of the pulmonary histopathologic findings. Arch Intern Med 1981; 141: 1005–1110.PubMedGoogle Scholar
  36. 36.
    Turton CW, Williams G, Green M. Cryptogenic obliterative bronchiolitis in adults. Thorax 1981; 36: 805–810.PubMedGoogle Scholar
  37. 37.
    Murphy KC, Atkins GJ, Offer RC, Hogg JC, Stein HB. Obliterative bronchiolitis in two rheumatoid arthritis patients treated with penicillamine. Arthritis Rheum 1981; 24: 557–560.PubMedGoogle Scholar
  38. 38.
    Wiener-Kronish JP, Solinger AM, Warnock ML, Churg A, Ordonez N, Golden JA. Severe pulmonary involvement in mixed connective tissue disease. Am Rev Respir Dis 1981; 124: 499–503.PubMedGoogle Scholar
  39. 39.
    Landensuo A, Mattila J, Vilppula A. Bronchiolitis in rheumatoid arthritis. Chest 1984; 85: 705–708.Google Scholar
  40. 40.
    Lyon MG, Bewtra C, Kenik JG, Hurley JA. Tubuloreticular inclusions in systemic lupus pneumonitis: Report of a case and review of the literature. Arch Pathol Lab Med 1984; 108: 599–600.PubMedGoogle Scholar
  41. 41.
    Kallenberg CGM, Jansen HM, Elema JD. The TH. Steroid-responsive interstitial pulmonary disease in systemic sclerosis. Monitoring by bronchoalveolar lavage. Chest 1984; 86: 489–492.PubMedGoogle Scholar
  42. 42.
    Constantopoulos SH, Papadimitriou CS, Moutsopoulous HM. Respiratory manifestations in primary Sjogren’s syndrome: a clinical, functional and histologic study. Chest 1985; 88: 226–229.PubMedGoogle Scholar
  43. 43.
    Konig G, Luderschmidt C, Hammer C, Adelmann-Grill BG, Braun-Falco O, Fruhmann G. Lung involvement in scleroderma. Chest 1984; 85: 318–324.PubMedGoogle Scholar
  44. 44.
    Yousem SA, Colby TV, Carrington CB. Lung biopsy in rheumatoid arthritis. Am Rev Respir Dis 1985; 131: 770–777.PubMedGoogle Scholar
  45. 45.
    Rossi GA, Bitterman PB, Rennard SI, Ferrans VJ, Crystal RG. Evidence for chronic inflammation as a component of the interstitial lung disease associated with progressive systemic sclerosis. Am Rev Respir Dis 1985; 131: 612–617.PubMedGoogle Scholar
  46. 46.
    Askin FB. Pulmonary disorders in the collagen vascular diseases. Hum Pathol 1990; 21: 465–466.PubMedGoogle Scholar
  47. 47.
    Helmers R, Galvin J, Hunninghake GW. Pulmonary manifestations associated with rheumatoid arthritis. Chest 1991; 100: 235–238.PubMedGoogle Scholar
  48. 48.
    Tazelaar HD, Viggiano RW, Pickersgill J, Colby TV. Interstitial lung disease in polymyositis and dermatomyositis: Clinical features and prognosis is correlated with hisologic findings. Am Rev Respir Dis 1990; 141: 727–733.PubMedGoogle Scholar
  49. 49.
    Yousem SA. The pulmonary pathologic manifestations of the CRST syndrome. Hum Pathol 1990; 21: 467–474.PubMedGoogle Scholar
  50. 50.
    Weinrib L, Sharma OP, Quismorio FP, Jr. A long term study of interstitial lung disease in systemic lupus erythematosus. Semin Arthritis Rheum 1990; 20: 48–56.PubMedGoogle Scholar
  51. 51.
    Cervera R, Ramirez G, Fernandez-Sola J, D’Crox D, et al. Antibodies to endothelial cells in dermatomyositis: Association with interstitial lung disease. Br Med J 1991; 302: 880–881.Google Scholar
  52. 52.
    Capron JP, Marti R, Rey JL, et al. Fibrosing alveolitis and hepatitis B surface antigen-associated chronic active hepatitis in a patient with immunoglobulin A deficiency. Am J Med 1979; 66: 874–878.PubMedGoogle Scholar
  53. 53.
    Turner-Warwick M. Fibrosing alveolitis and chronic liver disease. QJ Med 1968; 37: 133–149.Google Scholar
  54. 54.
    Lynne-Davies P, Sproule BJ. Pulmonary fibrosis and hepatitis. Can Med Assoc J 1967; 96: 1110–1112.PubMedGoogle Scholar
  55. 55.
    Jonard P, Geubel A, Wallon J, Rahier J, Dive C, Meunier H. Primary sclerosing cholangitis and idiopathic pulmonary fibrosis: A case report. Acta Clin Belg 1989;44:24–30.Google Scholar
  56. 56.
    Hughes EW. Familial interstitial pulmonary fibrosis. Thorax 1964; 19: 515–525.PubMedGoogle Scholar
  57. 57.
    Bonanni PP, Frymoyer JW, Jacox RF. A family study of idiopathic pulmonary fibrosis. Am J Med 1965; 39: 411–421.PubMedGoogle Scholar
  58. 58.
    Adelman AG, Chertokow G, Hayton RC. Familial fibrocystic pulmonary dysplasia: A detailed family study. Can Med Assoc J 1966; 95: 603–610.PubMedGoogle Scholar
  59. 59.
    Swaye P, VanOrdstrand HS, McCormack LJ, Wolpaw SE. Familial Hamman-Rich syndrome: report of eight cases. Dis Chest 1969; 55: 7–12.PubMedGoogle Scholar
  60. 60.
    Solliday NH, Williams JA, Gaensler EA, Coutu RE, Carrington CB. Familial chronic interstitial pneumonia. Am Rev Respir Dis 1973; 108: 193–204.PubMedGoogle Scholar
  61. 61.
    Davies BH, Tuddenham EGD. Familial pulmonary fibrosis associated with oculocutaneous albinism and platelet function defect: A new syndrome. Q J Med 1976; 45: 219–232.Google Scholar
  62. 62.
    Crystal RG, Fulmer JD, Roberts WC, Moss ML. Line BR, Reynolds HV. Idiopathic pulmonary fibrosis: Clinical, histologic, radiologic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med 1976; 85: 769–788.PubMedGoogle Scholar
  63. 63.
    Evans CC, Evans JM. HL-A in farmer’s lung. Lancet 1975;ii:975–976.Google Scholar
  64. 64.
    Turton CWG, Morris LM, Lawler SD, Turner-Warwick M. HLA in cryptogenic fibrosing alveolitis. Lancet 1978;i:507–508.Google Scholar
  65. 65.
    Varpela E, Tiilikaine A, Varpela N, Tukiainen P. High prevalences of HLA-B15 and HLA-DW6 in patients with cryptogenic fibrosing alveolitis. Tissue Antigens 1979; 14: 68–71.PubMedGoogle Scholar
  66. 66.
    Strimlan CV, Taswell HF, DeRemee RA, Kueppers F. HL-A antigens and fibrosing alveolitis. Am Rev Respir Dis 1977; 116: 1120–1121.PubMedGoogle Scholar
  67. 67.
    Briggs DC, Vaughan RW, Welsh KI, Myers A, du Bois RM, Black CM. Immunogenetic prediction of pulmonary fibrosis in systemic sclerosis. Lancet 1991; 338: 661–662.PubMedGoogle Scholar
  68. 68.
    Auerbach O, Stout AP, Hammond EC, Garfinkel L. Smoking habits and age in relation to pulmonary changes: Rupture of alveolar septums, fibrosis and thickening of walls of small arteries and arterioles. N Engl J Med 1963; 269: 1045–1054.PubMedGoogle Scholar
  69. 69.
    Auerbach O, Garfinkel L. Hammond EC. Relation of smoking and age to findings in the lung parenchyma: A microscopic study. Chest 1974; 65: 29–35.PubMedGoogle Scholar
  70. 70.
    Weiss W. Cigarette smoke, asbestos and small irregular opacities. Am Rev Respir Dis 1984; 130: 293–301.PubMedGoogle Scholar
  71. 71.
    Carrington CB, Gaensler EA, Coutu RE, Fitzgerald MX, Gupta RG. Natural history and treated course of usual and desquamative interstitial pneumonia. N Engl J Med 1978; 298: 802–809.Google Scholar
  72. 72.
    Turner Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis: Clinical features and their influence on survival. Thorax 1980; 35: 171–180.Google Scholar
  73. 73.
    Turner Warwick M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis and their influence on survival. Thorax 1980; 35: 593–599.Google Scholar
  74. 74.
    Rudd RM, Haslam PL, Turner Warwick M. Cryptogenic fibrosing alveolitis: Relationships of pulmonary physiology and bronchoalveolar lavage to treatment and prognosis. Am Rev Respir Dis 1981; 124: 1–8.PubMedGoogle Scholar
  75. 75.
    Stack BHR, Choo-Kang YFJ, Heard BE. The prognosis of cryptogenic fibrosing alveolitis. Thorax 1980; 35: 535–542.Google Scholar
  76. 76.
    Turner Warwick M, Lebowitz M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980; 35: 496 499.Google Scholar
  77. 77.
    Haslam PL, Turton CWG, Lukoszek A, et al. Bronchoalveolar lavage fluid cell counts in cryptogenic fibrosing alveolitis and their relation to therapy. Thorax 1980; 35: 328–329.PubMedGoogle Scholar
  78. 78.
    de Cremoux H, Bernaudin J, Laurent P, Brochard P, Bignon J. Interactions between cigarette smoking and the natural history of idiopathic pulmonary fibrosis. Chest 1990; 98: 71–76.PubMedGoogle Scholar
  79. 79.
    Winterbauer RH, Ludwig WR, Hammar SP. Clinical course, management and long term sequelae of respiratory failure due to influenza viral pneumonia. Johns Hopkins Med J 1977; 141: 148–155.PubMedGoogle Scholar
  80. 80.
    Pinsker KL, Schneyer B, Becker N, Kamholz SL. Usual interstitial pneumonia following Texas A2 influenza infection. Chest 1981; 80: 123–126.PubMedGoogle Scholar
  81. 81.
    Martin WJ II, McDougall JC. Cytomegalovirus infection with idiopathic pulmonary fibrosis: Diagnosis suggested by bronchoalveolar lavage. Chest 1983; 84: 500–502.PubMedGoogle Scholar
  82. 82.
    Verganon JM, De The G, Weynants M, Vincent JF, Mornex JF, Brone J. Cryptogenic fibrosing alveolitis and Epstein-Barr virus: An association?. Lancet 1984;ii:768–771.Google Scholar
  83. 83.
    Roggli VL. Scanning electron microscopic analysis of mineral fiber content of lung tissue in the evaluation of diffuse pulmonary fibrosis. Scanning Microsc 1991; 5: 71–83.PubMedGoogle Scholar
  84. 84.
    Gail DB, Lenfant CJM. Cells of the lung: Biology and clinical implications. Am Rev Respir Dis 1983; 127: 366–387.PubMedGoogle Scholar
  85. 85.
    Crapo JD, Barry BE, Gehr P, Bachofen M, Weibel ER. Cell number and cell characteristics of the normal human lung. Am Rev Respir Dis 1982; 125: 740–745.PubMedGoogle Scholar
  86. 86.
    Crapo JD, Young SL, Fram EK, Pinkerton KE, Barry BE, Crapo RD. Morphometric characteristics of cells in the alveolar region of mammalian lungs. Am Rev Respir Dis 1983; 128: S42 - S46.PubMedGoogle Scholar
  87. 87.
    Bowden DH. Cell turnover in the lung. Am Rev Respir Dis 1983; 128: 546 - S48.Google Scholar
  88. 88.
    Golde DW, Finley TN, Cline MJ. The pulmonary macrophage in acute leukemia. N Engl J Med 1974; 290: 875–878.PubMedGoogle Scholar
  89. 89.
    Kazmierowski JA, Gallin JI, Reynolds HY. Mechanism for the inflammatory response in primate lungs: Demonstration and partial characterization of an alveolar macrophage-derived chemotactic factor with preferential activity for polymorphonuclear leukocytes. J Clin Invest 1977; 59: 273–281.PubMedGoogle Scholar
  90. 90.
    Hunninghake GW, Gallin JI, Fauci AS. Immunologic reactivity of the lung: The in vivo and in vitro generation of a neutrophil chemotactic factor by alveolar macrophages. Am Rev Respir Dis 1978; 117: 15–23.PubMedGoogle Scholar
  91. 91.
    Golde DW, Finley TN, Cline MJ. Production of colony stimulating factor by human macrophages. Lancet 1972;ii:1397–1399.Google Scholar
  92. 92.
    Postlethwaite AE, Keski-Oja J, Balian G, Kung AH. Induction of fibroblast chemotaxis by fibronectin: Localization of the chemotactic region to a 140,000 molecular weight non-gelatin binding region. J Exp Med 1981; 153: 494–499.PubMedGoogle Scholar
  93. 93.
    Klebe RJ. Isolation of a collagen dependent cell attachment factor. Nature 1974; 250: 248–251.PubMedGoogle Scholar
  94. 94.
    Kelley J. Cytokines of the lung. Am Rev Respir Dis 1990; 141: 765–788.PubMedGoogle Scholar
  95. 95.
    Vignaud J, Allam M, Martinet N, Pech M, Plenat F, Martine Y. Presence of platelet-derived growth factor in normal and fibrotic lung is specifically associated with interstial macrophages, while both interstitial macrophages and alveolar epithelial cells express the c-sis proto-oncogene. Am J Respir Cell Mol Biol 1991; 5: 531–538.PubMedGoogle Scholar
  96. 96.
    Marinelli WA, Polunovsky VA, Harmon KR, Bitterman PB. Role of platelet-derived growth factor in pulmonary fibrosis. Am J Respir Cell Mol Biol 1991; 5: 503–504.PubMedGoogle Scholar
  97. 97.
    Everson MP, Chandler DB. Changes in distribution, morphology and tumor necrosis factor alpha secretion of alveolar macrophage subpopulations during the development of bleomycin-induced pulmonary fibrosis. Am J Pathol 1992; 140: 503–512.PubMedGoogle Scholar
  98. 98.
    Warren JS, Yabroff KR, Remick DG, et al. Tumor necrosis factor participates in the pathogenesis of acute immune complex alveolitis in the rat. J Clin Invest 1989; 84: 1873–1882.PubMedGoogle Scholar
  99. 99.
    Lynch JP, III, Standiford TJ, Rolfe MW, Kunkel SL, Strieter RM. Neutrophilic alveolitis in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1992; 145: 1433–1439.PubMedGoogle Scholar
  100. 100.
    Bitterman PB, Adelberg S, Crystal RG. Mechanisms of pulmonary fibrosis: spontaneous release of alveolar macrophage derived growth factor in the interstitial lung disorders. J Clin Invest 1983; 72: 1801–1813.PubMedGoogle Scholar
  101. 101.
    Dreisen RB, Schwarz MI, Theofilopoulous AN, Stanford RE. Circulating immune complexes in the idiopathic interstitial pneumonias. N Engl J Med 1978; 298: 353–357.Google Scholar
  102. 102.
    Razma AG, Lynch JP, Wilson BS, Ward PA, Kunke SL. Expression of Ia-like (DR) antigen ou human alveolar macrophages isolated by bronchoalveolar lavage. Am Rev Respir Dis 1984; 129: 419–424.PubMedGoogle Scholar
  103. 103.
    Hunninghake GW, Kawanami O, Ferrans VJ, et al. Characterization of the inflammatory and immune effector cells in the lung parenchyma of patients with interstitial lung disease. Am Rev Respir Dis 1981; 123: 407–412.PubMedGoogle Scholar
  104. 104.
    Hunninghake GW, Gudek JE, Young RC, Jr, Kawanami O, Ferrans VJ, Crystal RG. Maintenance of granuloma formation in pulmonary sarcoidosis by T-lymphocytes within the lung. N Engl J Med 1980; 302: 594–598.PubMedGoogle Scholar
  105. 105.
    Schrier DJ, Phan SH, McGarry BM. The effects of nude (nu/nu) mutation on bleomycin-induced pulmonary fibrosis. A biochemical evaluation. Am Rev Respir Dis 1983; 127: 614–617.PubMedGoogle Scholar
  106. 106.
    Wahl SM, Wahl LM, McCarthy JB. Lymphocyte mediated activation of fibroblasts proliferation and collagen production. J Immunol 1978; 121: 942–946.PubMedGoogle Scholar
  107. 107.
    Reynolds HY, Fulmen JD, Kazmierowski JA, Roberts WC, Frank MM, Crystal RG. Analysis of cellular and protein content of bronchoalveolar lavage fluid from patients with idiopathic pulmonary fibrosis and chronic hypersensitivity pneumonitis. J Clin Invest 1977; 59: 165–175.PubMedGoogle Scholar
  108. 108.
    Weinberger SE, Kelman JA, Elson NA, et al. Bronchoalveolar lavage in interstitial lung disease. Ann Intern Med 1978; 89: 459–466.PubMedGoogle Scholar
  109. 109.
    Gadeck JE, Kelman JA, Fells G, et al. Collagenase in the lower respiratory tract of patients with idiopathic pulmonary fibrosis. N Engl J Med 1979; 301: 737–742.Google Scholar
  110. 110.
    Phan SH, Schrier D, McGarry B, Duque RE. Effect of the beige mutation on bleomycin induced pulmonary fibrosis in mice. Am Rev Respir Dis 1983; 127: 456–459.PubMedGoogle Scholar
  111. 111.
    Snider GL. Interstitial pulmonary fibrosis-which cell is the culprit? Am Rev Respir Dis 1983; 127: 540–544.Google Scholar
  112. 112.
    Strausz J, Müller-Quernheim J, Steppling H, Ferlinz R. Oxygen radical production by alveolar inflammatory cells in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1990; 141: 124–128.PubMedGoogle Scholar
  113. 113.
    Nettelbladt O, Hällgren R. Hyaluronan (hyaluronic acid) in bronchoalveolar lavage fluid during the development of bleomycin-induced alveolitis in the rat. Am Rev Respir Dis 1989; 140: 1028–1032.PubMedGoogle Scholar
  114. 114.
    Montano M, Ramos C, Gonzalez G, Vadillo F, Pardo A, Selman M. Lung collagenase inhibitors and spontaneous and latent collagenase activity in idiopathic pulmonary fibrosis and hypersensitivity pneumonitis. Chest 1989; 96: 1115–1119.PubMedGoogle Scholar
  115. 115.
    Noguchi H, Kephart GM, Colby TV, Gleich GJ. Tissue eosinophilia and eosinophil degranulation in syndromes associated with fibrosis. Am J Pathol 1992; 140: 521–528.PubMedGoogle Scholar
  116. 116.
    Pennington DW, Ruoss SJ, Gold WM. Dog mastocytoma cells secrete a growth factor for fibroblasts. Am J Respir Cell Mol Biol 1992; 6: 625–632.PubMedGoogle Scholar
  117. 117.
    Fullmer JD, Biekowski RS, Cowan MJ, et al. Collagen concentration and rates of synthesis in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1980; 122: 289–301.Google Scholar
  118. 118.
    Madri JA, Furthmayr H. Collagen polymorphism in the lung: An immunochemical study of pulmonary fibrosis. Hum Pathol 1980; 11: 353–366.PubMedGoogle Scholar
  119. 119.
    Raghu G, Striker LJ, Hudson LD, Striker GE. Extracellular matrix in normal and fibrotic human lungs. Am Rev Respir Dis 1985; 131: 281–289.PubMedGoogle Scholar
  120. 120.
    Corrin B, Dewar A, Rodriguez-Roisin R, Turner-Warwick M. Fine structural changes in cryptogenic fibrosing alveolitis and asbestos. J Pathol 1985; 147: 107–119.PubMedGoogle Scholar
  121. 121.
    Basset F, Ferrans VJ, Soler P, Takemura T, Fukuda Y, Crystal RG. Intraluminal fibrosis in interstitial lung disorders. Am J Pathol 1986; 122: 443–461.PubMedGoogle Scholar
  122. 122.
    Kuhn C, III, Boldt J, King TE, Jr., Crouch E, Vartio T, McDonald JA. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 1989; 140: 1693–1703.PubMedGoogle Scholar
  123. 123.
    Kuhn C. Patterns of lung repair: A morphologist’s view. Chest 1991; 99: 11S - 14S.PubMedGoogle Scholar
  124. 124.
    Kuhns C, McDonald JA. The roles of myofibroblasts in idiopathic pulmonary fibrosis: Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 1991; 138: 1257–1265.Google Scholar
  125. 125.
    MacDonald JA. Idiopathic pulmonary fibrosis: A paradigm for lung injury and repair. Chest 1991; 99 (Suppl.) 87S - 93S.Google Scholar
  126. 126.
    Hyde DM, Nakasima JM, Harris JA, Giri SN. Epithelial injury is a critical factor in the development of pulmonary fibrosis following multiple episodes of inflammation. Chest 1991; 99: 28S.Google Scholar
  127. 127.
    Ward PA. Overview of the process of cellular injury in interstitial lung disease. Chest 1991; 100: 230–232.PubMedGoogle Scholar
  128. 128.
    Osborne DR. The Lung: Segmental anatomy and nonneoplastic diseases. In: Godwin JD, ed. Computed tomography of the chest. Philadelphia: JB Lippincott Co, 1984; 160–186.Google Scholar
  129. 129.
    Müller NL, Miller RR. Computed tomography of chronic diffuse infiltratitive lung disease. Am Rev Respir Dis 1990; 142: 1206–1215.PubMedGoogle Scholar
  130. 130.
    Swensen SJ, Aughenbaugh GL, Brown LR. High resolution computed tomography of the lung. Mayo Clin Proc 1989; 64: 1284–1294.PubMedGoogle Scholar
  131. 131.
    Gamsu G. High-resolution computed tomography of diffuse lung disease. Invest Radiol 1989; 24: 805–812.PubMedGoogle Scholar
  132. 132.
    Newman SL, Michael RP, Wang NS. Lingular lung biopsy: Is it representative? Am Rev Respir Dis 1985; 132: 1084–1086.PubMedGoogle Scholar
  133. 133.
    Wetstein L. Sensitivity and specificity of lingular segmental biopsies of the lung. Chest 1986; 90: 383–386.PubMedGoogle Scholar
  134. 134.
    Meyer EC, Liebow AA. Relationship of interstitial pneumonia, honeycombing and atypical epithelial proliferation to cancer of the lung. Cancer (Phila) 1965; 18: 322–351.Google Scholar
  135. 135.
    Haddad R, Maasaro D. Idiopathic diffuse interstitial pulmonary fibrosis (fibrosing alveolitis), atypical epithelial proliferation and lung cancer. Am J Med 1968; 44: 211–219.Google Scholar
  136. 136.
    Fraire AE, Greenberg SD. Carcinoma and diffuse interstitial fibrosis of lung. Cancer 1973; 31: 1078–1086.PubMedGoogle Scholar
  137. 137.
    Turner-Warwick M, Lebowitz M, Burrows B, Johnson A. Cryptogenic fibrosing alveolitis and lung cancer. Thorax 1980; 35: 496–499.PubMedGoogle Scholar
  138. 138.
    Woodcock-Mitchell J, Adler KB, Low RB. Immunohistochemical identification of cell types in normal and in bleomycin-induced fibrotic rat lung: Cellular origins of interstitial cells. Am Rev Respir Dis 1984; 130: 910–916.PubMedGoogle Scholar
  139. 139.
    Goto T, Befus D, Low R, Bienstock J. Mast cell heterogeneity and hyperplasia in bleomycin-induced pulmonary fibrosis of rats. Am Rev Respir Dis 1984; 130: 797–802.PubMedGoogle Scholar
  140. 140.
    Rowden G. The Langerhans cell. CRC Crit Rev Immunol 1981; 3: 95–180.Google Scholar
  141. 141.
    Basset F, Soler P, Wyllie L, Mazin F, Turiaf J. Langerhans cells and the lung interstitium. Ann NY Acad Sci 1976; 278: 599–611.PubMedGoogle Scholar
  142. 142.
    Kawanami O, Basset F, Ferrans VJ, Soler P, Crystal RG. Pulmonary Langerhans cells in patients with fibrotic lung disease. Lab Invest 1981; 44: 227–233.PubMedGoogle Scholar
  143. 143.
    Hammar S, Bockus D, Remington F, Bartha M. The widespread distribution of Langerhans cells in pathologic tissues: An ultrastructural and immunohistochemical study. Hum Pathol 1986; 17: 894–905.PubMedGoogle Scholar
  144. 144.
    Hammar SP, Winterbauer RH, Bockus D, Remington F, Friedman S. Idiopathic fibrosing alveolitis: A review with emphasis on ultrastructural and immunohistochemical features. Ultrastruct Pathol 1985; 9: 345–372.PubMedGoogle Scholar
  145. 145.
    Colby TV, Lombard C. Histocytosis X in the lung. Hum Pathol 1983; 14: 847–856.PubMedGoogle Scholar
  146. 146.
    Basset F, Corrin B, Spencer H, et al. Pulmonary histiocytosis X. Am Rev Respir Dis 1978; 118: 811–820.PubMedGoogle Scholar
  147. 147.
    Hammar S, Winterbauer RH, Gilmore T, Hallman KO, Bush W, Dail DH. Pulmonary histiocytosis X: A clinico-pathologic study of 3 cases. (manuscript submitted to Ultra Pathol)Google Scholar
  148. 148.
    Hammar SP, Winterbauer RH, Bockus D, Remington F, Sale GE, Myers JD. Endothelial cell damage and tubuloreticular structures in interstitial lung disease associated with collagen vascular diseases and viral pneumonia. Am Rev Respir Dis 1983; 127: 77–84.PubMedGoogle Scholar
  149. 149.
    Bockus D, Remington F, Luu J, Friedman S, Bean M, Hammar SP. Induction of cylindrical confronting cisternae (AIDS inclusions) in Daudi lymphoblastoid cells by recombinant alpha interferon. Hum Pathol 1988; 19: 78–82.PubMedGoogle Scholar
  150. 150.
    Ramaswamy G, Jagadha V, Tchertkoff V. Diffuse alveolar damage and interstitial fibrosis in acquired immunodeficiency syndrome patient without concurrent pulmonary infection. Arch Pathol Lab Med 1985; 109: 408–412.PubMedGoogle Scholar
  151. 151.
    Grieco MH, Chinoy-Acharya P. Lymphocytic interstitial pneumonia associated with the acquired immune deficiency syndrome. Am Rev Respir Dis 1985; 131: 952–955.PubMedGoogle Scholar
  152. 152.
    Solal-Celingny T, Couderc LJ, Herman D, et al. Lymphoid interstitial pneumonitis in acquired immunodeficiency syndrome-related complex. Am Rev Respir Dis 1985; 131: 956–960.Google Scholar
  153. 153.
    DeStefano E, Friedman RM, Friedman-Klein AE, et al. Acid labile human leukocyte interferon in homosexual men with Kaposi’s sarcoma and lymphadenopathy. J Infect Dis 1982; 146: 451–455.PubMedGoogle Scholar
  154. 154.
    Epler GR, Colby TV, McLoud TC, Carrington CB, Gaensler EA. Bronchiolitis obliterans organizing pneumonia. N Engl J Med 1985; 312: 152–158.PubMedGoogle Scholar
  155. 155.
    Katzenstein AA, Myers JL, Prophet WD, Corley LS, Shin MS. Bronchiolitis obliterans and usual interstitial pneumonia: A comparative clinocpathologic study. Am J Surg Pathol 1986; 10: 373–381.PubMedGoogle Scholar
  156. 156.
    Colby T, Churg AC. Patterns of pulmonary fibrosis. In: Sommers SC, Rosen PP, Fechner RE, eds, Pathology annual. Norwalk: Appleton-Century-Crofts, 1986, Part 2: 277–310Google Scholar
  157. 157.
    DeHoratius RJ, Abruzzo JL, Williams RC. Immunofluorescent and immunologic studies of rheumatoid lung. Arch Intern Med 1972; 129: 441–446.PubMedGoogle Scholar
  158. 158.
    Clinicopathologic conference. N Engl J Med 1975; 293: 136–144.Google Scholar
  159. 159.
    Wiener-Kronish JP, Solinger AM, Warnock ML, Churg A, Ordonez N, Golden JA. Severe pulmonary involvement in mixed connective tissue disease. Am Rev Respir Dis 1981; 124: 499–503.PubMedGoogle Scholar
  160. 160.
    Hogan PG, Donald KJ, McEvoy JDS. Immunofluorescence studies of lung biopsy tissue. Am Rev Respir Dis 1978; 118: 537–545.PubMedGoogle Scholar
  161. 161.
    Levin DC, Wicks AB, Ellis JH. Transbronchial lung biopsy via the fiberoptic bronchoscope. Am Rev Respir Dis 1974; 110: 4–12.PubMedGoogle Scholar
  162. 162.
    Smith CW, Murray GF, Wilcox BR, Starek PJK, Delany DJ. The role of transbronchial lung biopsy in diffuse pulmonary disease. Ann Thorac Surg 1977; 24: 54–58.PubMedGoogle Scholar
  163. 163.
    Jenkins R, Myerowtiz RL, Kavic T, Slasky S. Diagnostic yield of transbronchoscopic biopsies. Am J Clin Pathol 1979; 72: 926–930.PubMedGoogle Scholar
  164. 164.
    Wall CP, Gaensler EA, Carrington CB, Hayes JA. Comparison of transbronchial and open biopsies in chronic infiltrative lung disease. Am Rev Respir Dis 1981; 123: 280–290.PubMedGoogle Scholar
  165. 165.
    Reynolds HY, Newball HH. Analysis of proteins and respiratory cells obtained from human lungs by bronchial lavage. J Lab Clin Med 1974; 84: 559–573.PubMedGoogle Scholar
  166. 166.
    Dohn MN, Baughman RP. Effect of changing instilled volume for bronchoalveolar lavage in patients with interstitial lung disease. Am Rev Respir Dis 1985; 132: 390–392.PubMedGoogle Scholar
  167. 167.
    Cantin A, Begin R, Rola-Pleszczynski M, Boyleau R. Heterogeneity of bronchoalveolar lavage cellularity in stage III pulmonary sarcoidosis. Chest 1983; 83: 485–486.PubMedGoogle Scholar
  168. 168.
    Gelb AF, Dreisen RB, Epstein JD, et al. Immune complexes, gallium lung scans and bronchoalveolar lavage in idiopathic interstitial pneumonitis-fibrosis: A structure-function clinical study. Chest 1983; 84: 148–153.PubMedGoogle Scholar
  169. 169.
    Davis GS, Brody AR, Craighead JE. Analysis of airspace and interstitial mononuclear cell populations in human diffuse interstitial lung disease. Am Rev Respir Dis 1978; 118: 7–16.PubMedGoogle Scholar
  170. 170.
    Hunninghake GW, Kawanami O, Ferrans VJ, Young RC, Jr, Roberts WC. Crystal RG. Characterization of inflammatory and immune effector cells in the lung parenchyma of patients with interstitial lung disease. Am Rev Respir Dis 1981; 123: 407–412.PubMedGoogle Scholar
  171. 171.
    Haslam PL, Turton C, Heard B, et al. Bronchoalveolar lavage in pulmonary fibrosis: Comparison of cells obtained with lung biopsy and clinical features. Thorax 1980; 35: 9–18.Google Scholar
  172. 172.
    Stack BH. Choo-Kang YF, Heard BE. The prognosis of cryptogenic fibrosing alveolitis. Thorax 1972; 27: 435–542.Google Scholar
  173. 173.
    Rudd RM, Haslam PL, Turner-Warwick M. Cryptogenic fibrosing alveolitis: Relationships of pulmonary physiology and bronchoalveolar lavage to response to treatment and prognosis. Am Rev Respir Dis 1981; 124: 1–8.PubMedGoogle Scholar
  174. 174.
    Haslam PL. Circulating immune complexes in patients with cryptogenic fibrosing alveolitis. Clin Exp Immunol 1979; 37: 381–390.PubMedGoogle Scholar
  175. 175.
    Winterbauer RH. The treatment of idiopathic pulmonary fibrosis. Chest 1991; 100: 233–235.PubMedGoogle Scholar
  176. 176.
    Martinet Y, Haslam PL, Turner-Warwick M. Clinical significance of circulating immune complexes in “lone” cryptogenic fibrosis alveolitis and those with associated connective tissue disorders. Clin Allergy 1984; 14: 491–497.PubMedGoogle Scholar
  177. 177.
    Winterbauer RH, Hammar SP. Tubuloreticular structures: An electron microscopic marker of cyclophosphamide responsive fibrosing alveolitis. Am Rev Respir Dis 1982; 125: 91A.Google Scholar

Copyright information

© Springer Science+Business Media New York 1994

Authors and Affiliations

  • Samuel P. Hammar

There are no affiliations available

Personalised recommendations